CN107812122A - 一种治疗结石的药物组合物及其制备方法 - Google Patents
一种治疗结石的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN107812122A CN107812122A CN201711241789.XA CN201711241789A CN107812122A CN 107812122 A CN107812122 A CN 107812122A CN 201711241789 A CN201711241789 A CN 201711241789A CN 107812122 A CN107812122 A CN 107812122A
- Authority
- CN
- China
- Prior art keywords
- parts
- bulk drug
- composition
- weighed
- calculus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 62
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 240000008027 Akebia quinata Species 0.000 claims abstract description 18
- 235000007756 Akebia quinata Nutrition 0.000 claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 18
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 18
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000010931 gold Substances 0.000 claims abstract description 18
- 229910052737 gold Inorganic materials 0.000 claims abstract description 18
- 239000004576 sand Substances 0.000 claims abstract description 18
- 241000522190 Desmodium Species 0.000 claims abstract description 17
- 230000000295 complement effect Effects 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 24
- 241000736199 Paeonia Species 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 239000006187 pill Substances 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 208000000913 Kidney Calculi Diseases 0.000 claims description 8
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 8
- -1 Granula Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 208000001130 gallstones Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004575 stone Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000737253 Lygodium japonicum Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000000014 Ureteral Calculi Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010006987 Calculus bladder Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 201000000210 bladder calculus Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗结石的药物组合物,它是由下述重量配比的原料药制备而成:白茅根120‑180份、海金砂80‑120份、白芍24‑36份、金钱草24‑36份、白术24‑36份、茯苓24‑36份、木通12‑18份。本发明还提供了该组合物的制备方法和用途。本发明提供的组合物,配伍合理,各药味相辅相成,无毒副作用,可将结石由大化小,由小化无,能有效治疗结石,具有较强的实际应用价值。
Description
技术领域
本发明涉及一种治疗结石的药物组合物及其制备方法和用途。
背景技术
结石病是人体异常矿化所致的一种以钙盐或脂类积聚成形而引起的一种疾病,是外科常见病,包括泌尿系结石、消化系结石,例如肾结石,输尿管结石等。结石静止时,病人多无不适,一旦嵌顿非常痛苦。
中医认为,结石是因体内湿热浊邪蕴结不散,久经煎熬形成的砂石样病理产物,为继发性病因之一。古代医家所论结石主要是导致石淋病的肾与膀胱结石,如《诸病源候论·诸淋证候》指出:“石淋者,肾主水,水结则化为石,故肾客砂石,肾虚为热所乘。”结石可发生于机体的许多部位,以肝胆、肾、膀胱和胃为常见。结石是有形质的病理产物,其形状各异,常见的结石有泥砂样结石,圆形或不规则形状的结石等,且大小不一。一般来说,结石小者,易于排出;而结石较大者,难于排出,多留滞而致病。
目前西医针对结石采取的主要治疗方案多为摘除手术和激光碎石。这虽然可以在短时间内减缓或消除患者的痛苦,但并没有解决疾病的第一原因。因为体内的湿热环境并没有改善,所以大部分肾结石患者需要反复做激光碎石手术。就好比做开水的水壶,长了水垢后我们可以用人工的方式把水垢祛除,但是只要让水壶继续做开水,没多久水垢就会再长出来,结石也是同样的道理。因此,以中医理论为指导,精准辨证、精准配方,将会为广大的结石患者带来福音。
发明内容
本发明的目的在于提供一种能有效治疗结石的药物组合物及其制备方法和用途。
本发明提供了一种治疗结石的药物组合物,它是由下述重量配比的原料药制备而成:
白茅根125-180份、海金砂80-115份、白芍24-36份、金钱草24-36份、白术24-36份、茯苓24-36份、木通12-17份。
海金沙:为海金沙科植物海金沙Lygodium japonicum(Thunb.)Sw.的干燥成熟孢子。
其中,它是由下述重量配比的原料制备而成:
白茅根136-170份、海金砂80-110份、白芍28-33份、金钱草28-33份、白术28-33份、茯苓28-33份、木通14-16份。
其中,它是由下述重量配比的原料制备而成:
白茅根150份、海金砂100份、白芍30份、金钱草30份、白术30份、茯苓30份、木通15份。
其中,所述组合物是以白茅根、海金砂、白芍、金钱草、白术、茯苓和木通的药粉,或者水或有机溶剂提取物为活性成分,加入药学上可接受的辅料或辅助性成分制备而成的制剂。
本发明所述药学上可接受的辅料,是指除活性成分以外包含在剂型中的物质,包括但不仅限于填充剂(稀释剂)、润滑剂(助流剂或抗粘着剂)、分散剂、湿润剂、粘合剂、调节剂、增溶剂、抗氧剂、抑菌剂、乳化剂、崩解剂等。粘合剂包含糖浆、阿拉伯胶、明胶、山梨醇、黄芪胶、纤维素及其衍生物(如微晶纤维素、羧甲基纤维素钠、乙基纤维素或羟丙甲基纤维素等)、明胶浆、糖浆、淀粉浆或聚乙烯吡咯烷酮等;填充剂包含乳糖、糖粉、糊精、淀粉及其衍生物、纤维素及其衍生物、无机钙盐(如硫酸钙、磷酸钙、磷酸氢钙、沉降碳酸钙等)、山梨醇或甘氨酸等;润滑剂包含微粉硅胶、硬脂酸镁、滑石粉、氢氧化铝、硼酸、氢化植物油、聚乙二醇等;崩解剂包含淀粉及其衍生物(如羧甲基淀粉钠、淀粉乙醇酸钠、预胶化淀粉、改良淀粉、羟丙基淀粉、玉米淀粉等)、聚乙烯吡咯烷酮或微晶纤维素等;湿润剂包含十二烷基硫酸钠、水或醇等;抗氧剂包含亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、二丁基苯酸等;抑菌剂包含0.5%苯酚、0.3%甲酚、0.5%三氯叔丁醇等;调节剂包含盐酸、枸橼酸、氢氧化钾(钠)、枸橼酸钠及缓冲剂(包括磷酸二氢钠和磷酸氢二钠)等;乳化剂包含聚山梨酯-80、脂肪酸山梨坦、普流罗尼克F-68,卵磷酯、豆磷脂等;增溶剂包含吐温-80、胆汁、甘油等。
所述药学上可接受的辅助性成分,它具有一定生理活性,但该成分的加入不会改变上述化合物或衍生物在疾病治疗过程中的主导地位,而仅仅发挥辅助功效,这些辅助功效仅仅是对该成分已知活性的利用,是医药领域惯用的辅助治疗方式。若将上述辅助性成分与本发明化合物配合使用,仍然应属于本发明保护的范围。
其中,所述制剂为口服制剂。
其中,所述口服制剂为汤剂、膏剂、口服液、颗粒剂、胶囊剂、丸剂、片剂、散剂。
本发明还提供了上述组合物的制备方法,它包括如下步骤:
a、称取各重量配比的原料;
b、将原料药直接打粉,或加水或有机溶剂提取后,加入药学上可接受的辅料或辅助性成分制备而成。
水提物或以药粉入药,均是中药传统使用方式,水提后,由于水的溶解范围广,能够将大部分有效成分溶出,使药物更容易被人体吸收,起效更快,例如汤剂等给药形式;以原粉入药,药粉的表面积较大,也有利于药材中有效成分在体内的吸收,但药材未经提取,有效成分仍需在体内溶出再吸收,其起效相对水提物较慢,但也同时削弱了药材中有害成分对人体造成的毒副反应,适合于长期服用,如将原粉制备成丸剂等给药形式。目前在制药过程中,乙醇作为溶剂对药物进行提取,也是最为常见的提取方式之一,乙醇为半极性溶剂,溶解性能界于极性与非极性溶剂之间,可以溶解水溶性的某些成分,也能溶解非极性溶剂溶解的一些成分,通常用乙醇提取代替水煎,从而避免大量无效成分的溶出,提高有效成分的浓度和提取效率,不过乙醇的价格较水贵,在现代制药工业大生产中,为了节省生产成本,通常还是以水煎为主。在本发明已知组合物的水提物具有生理活性的情况下,为了适应各种生产和使用时的需求,可以任选水提、原粉、醇提或它们的组合方法来制备具体的剂型。
其中,具体制备方法如下:
片剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩、加入辅料或辅助性成分,制粒、整粒、压片,即得;
汤剂:称取原料药,煎煮,过滤,即得;
散剂:称取原料药,打粉,过筛,即得;
颗粒剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩、干燥,加入辅料或辅助性成分,混匀,制粒、整粒、干燥,即得;
胶囊剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩干燥,加入辅料或辅助性成分,混匀,装胶囊,即得;
水丸:称取原料药,打粉,过筛,加入赋形剂,水泛丸,干燥,即得;
蜜丸:称取原料药,打粉,过筛,加入蜂蜜,制丸,干燥,即得;
滴丸:称取原料药,加水或有机溶剂提取,过滤,滤液中加入基质,混匀加热融化,滴入不相混溶的冷凝液中冷凝,即得。
所述的有机溶剂为不同浓度的乙醇,如25%-95%的乙醇。
本发明还提供了上述组合物在制备治疗结石的药物中的用途。
其中,所述药物为治疗胆结石、肾结石、膀胱结石或尿路结石的药物。
结石主要是由于脏腑本虚,湿热浊邪乘虚而入,蕴郁积聚不散,或湿热煎熬日久而成。常与饮食、情志等有关。嗜食辛辣,喜食肥甘厚味,或嗜酒太过,影响脾胃运化,蕴生湿热,内结于胆,湿热煎熬,日久可形成胆结石;湿热下注,蕴结于下焦,日久可形成肾或膀胱结石。情志失调,肝气郁结,疏泄失职,胆汁排泄不利而郁结,气滞湿阻血瘀日久化热,郁蒸煎熬而成结石。
本发明药物组合物中,以白茅根、海金砂为君药,清热解毒、利尿通淋;白芍、金钱草为臣药,平肝潜阳、化石渗湿,佐以白术、茯苓、木通,利水通淋,泻热止痛。
本发明药物组合物治疗结石之机理为:通过清利肝胆湿热,改变体内的湿热环境,使身体恢复平衡状态,达到从根本上治疗结石的目的;本发明药物组合物配伍合理,各药味相辅相成,可将结石由大化小,由小化无,对结石具有良好的治疗效果,临床治愈率高,而且本发明组合物安全性好,无毒副作用,使用方便,为临床提供了一种新的药物选择。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
下面以实施例作进一步说明,但本发明不局限于这些实施例。
实施例1本发明药物片剂的制备
取白茅根150g、海金砂100g、白芍30g、金钱草30g、白术30g、茯苓30g、木通15g,打粉,粉末直接压片,即得片剂。
实施例2本发明药物片剂的制备
取白茅根136g、海金砂80g、白芍28g、金钱草28g、白术28g、茯苓28g、木通16g,加水煎煮提取、浓缩成浸膏,加入淀粉制粒、整粒、压片,即得片剂。
实施例3本发明药物胶囊剂的制备
取白茅根170g、海金砂110g、白芍33g、金钱草33g、白术33g、茯苓33g、木通14g,加水煎煮提取、浓缩成浸膏,加入辅料,混匀,分装,即得胶囊剂。
实施例4本发明药物水丸的制备
取白茅根125g、海金砂80g、白芍24g、金钱草24g、白术24g、茯苓24g、木通17g,打粉,过筛,加入赋形剂,水泛丸,干燥,即得水丸。
实施例5本发明药物蜜丸的制备
取白茅根180g、海金砂115g、白芍36g、金钱草36g、白术36g、茯苓36g、木通12g,打粉,过筛,加入蜂蜜,制丸,干燥,即得蜜丸。
实施例6本发明药物汤剂的制备
取白茅根170g、海金砂110g、白芍36g、金钱草24g、白术32g、茯苓32g、木通16g,加水浸泡煎煮,合并滤液,过滤,即得汤剂。
实施例7本发明药物片剂的制备
取白茅根140g、海金砂100g、白芍28g、金钱草33g、白术30g、茯苓30g、木通15g,用乙醇提取,得到乙醇提取液,浓缩成浸膏,加入淀粉制粒、整粒、压片,即得片剂。
实施例8本发明药物口服液的制备
取白茅根160g、海金砂90g、白芍32g、金钱草30g、白术28g、茯苓33g、木通15g,加水浸泡煎煮,合并滤液,浓缩,灌封,灭菌,即得口服液。
以下用试验例的方式说明本发明的有益效果:
试验例1本发明药物组合物治疗结石的临床疗效
1实验材料
1.1实验药物 本发明药物组合物,由实施例1制备而成。
1.2患者资料 观察病例共45例,年龄平均44岁。
2实验方法
2.1纳入病例标准:①确诊为尿路结石包括肾结石、输尿管结石、膀胱结石及尿道结石的患者。②符合胆石症诊断的患者。
2.2排除病例标准:①妊娠或哺乳期妇女,对本药过敏者。②合并有心血管、肝、肾和造血系统等严重原发性疾病,精神病患者。③凡不符合纳入标准,未按规定用药,无法判断疗效或资料不全等影响疗效或安全性判断者。
2.3疗效判断
显效:服药1-2个疗程后,症状和体征消失,影像学检查,结石消失。
有效:服药1-2个疗程后,症状和体征有减轻,影像学检查,结石较治疗前减少或变小者。
无效:服药1-2个疗程后,症状和体征有减轻,或无变化,影像学检查,结石无改变者。
2.4给药方法
服药2个月:其中前10天,每日2-3次,每次服用的药物的重量相当于6克生药;以后每日2次,每次服用的药物的重量相当于3克生药。
3实验结果
实验结果说明,服用2个月可见明显效果,本发明药物组合物,总有效率96%,本发明药物组合物能有效治疗结石。
试验例2本发明药物组合物治疗结石的典型病例
柳XX,男性,43岁,2007年肾结石、尿路结石发病,未做激光碎石手术,服用本药40天后一切不适症状消失,至今未再发病。
综上,本发明组合物配伍合理,对结石具有良好的治疗效果,临床治愈率高,而且本发明组合物安全性好,无毒副作用,使用方便,临床应用前景良好。
Claims (10)
1.一种治疗结石的药物组合物,其特征在于:它是由下述重量配比的原料药制备而成:
白茅根125-180份、海金砂80-115份、白芍24-36份、金钱草24-36份、白术24-36份、茯苓24-36份、木通12-17份。
2.根据权利要求1所述的药物组合物,其特征在于:它是由下述重量配比的原料制备而成:
白茅根136-170份、海金砂80-110份、白芍28-33份、金钱草28-33份、白术28-33份、茯苓28-33份、木通14-16份。
3.根据权利要求2所述的药物组合物,其特征在于:它是由下述重量配比的原料制备而成:
白茅根150份、海金砂100份、白芍30份、金钱草30份、白术30份、茯苓30份、木通15份。
4.根据权利要求1-3任意一项所述的组合物,其特征在于:所述组合物是以白茅根、海金砂、白芍、金钱草、白术、茯苓和木通的药粉,或者水或有机溶剂提取物为活性成分,加入药学上可接受的辅料或辅助性成分制备而成的制剂。
5.根据权利要求4所述的组合物,其特征在于:所述制剂为口服制剂。
6.根据权利要求5所述的组合物,其特征在于:所述口服制剂为汤剂、膏剂、口服液、颗粒剂、胶囊剂、丸剂、片剂、散剂。
7.权利要求1-6任意一项所述的组合物的制备方法,其特征在于:它包括如下步骤:
a、称取各重量配比的原料;
b、将原料药直接打粉,或加水或有机溶剂提取后,加入药学上可接受的辅料或辅助性成分制备而成。
8.根据权利要求7所述的制备方法,其特征在于:具体制备方法如下:
片剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩、加入辅料或辅助性成分,制粒、整粒、压片,即得;
汤剂:称取原料药,煎煮,过滤,即得;
散剂:称取原料药,打粉,过筛,即得;
颗粒剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩、干燥,加入辅料或辅助性成分,混匀,制粒、整粒、干燥,即得;
胶囊剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩干燥,加入辅料或辅助性成分,混匀,装胶囊,即得;
水丸:称取原料药,打粉,过筛,加入赋形剂,水泛丸,干燥,即得;
蜜丸:称取原料药,打粉,过筛,加入蜂蜜,制丸,干燥,即得;
滴丸:称取原料药,加水或有机溶剂提取,过滤,滤液中加入基质,混匀加热融化,滴入不相混溶的冷凝液中冷凝,即得。
9.权利要求1-6任意一项所述的组合物在制备治疗结石的药物中的用途。
10.根据权利要求9所述的用途,其特征在于:所述药物为治疗胆结石、肾结石、膀胱结石或尿路结石的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711241789.XA CN107812122A (zh) | 2017-11-30 | 2017-11-30 | 一种治疗结石的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711241789.XA CN107812122A (zh) | 2017-11-30 | 2017-11-30 | 一种治疗结石的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107812122A true CN107812122A (zh) | 2018-03-20 |
Family
ID=61605164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711241789.XA Pending CN107812122A (zh) | 2017-11-30 | 2017-11-30 | 一种治疗结石的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107812122A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110765A (zh) * | 2013-02-18 | 2013-05-22 | 于浩 | 一种治疗肾结石中药 |
CN104083659A (zh) * | 2014-07-07 | 2014-10-08 | 广西正堂药业有限责任公司 | 一种治疗结石的中药制剂 |
CN106266322A (zh) * | 2016-08-31 | 2017-01-04 | 李朝彬 | 治疗肾结石的药物组合物 |
-
2017
- 2017-11-30 CN CN201711241789.XA patent/CN107812122A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110765A (zh) * | 2013-02-18 | 2013-05-22 | 于浩 | 一种治疗肾结石中药 |
CN104083659A (zh) * | 2014-07-07 | 2014-10-08 | 广西正堂药业有限责任公司 | 一种治疗结石的中药制剂 |
CN106266322A (zh) * | 2016-08-31 | 2017-01-04 | 李朝彬 | 治疗肾结石的药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT5433B (lt) | Farmacinė kompozicija skirta gydyti širdies kraujagyslių smegenų kraujagyslių ir susirgimus | |
CN104000944B (zh) | 一种具有温肾壮阳的保健品或药物组合物及其制备方法和用途 | |
CN107913374A (zh) | 一种治疗结石的药物组合物及其制备方法 | |
CN102895620A (zh) | 一种甘草泻心汤整合型新剂型制备技术及其生产方法 | |
CN107812122A (zh) | 一种治疗结石的药物组合物及其制备方法 | |
CN107929354A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
US20220395539A1 (en) | Traditional chinese medicine composition for treating psoriasis, preparation method therefor and use thereof | |
CN108014237A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
CN108126077A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
CN1083271C (zh) | 治疗泌尿系结石的药物 | |
CN108125237A (zh) | 一种镇咳祛痰抗炎的保健品及其制备工艺 | |
CN107929400A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN109568437A (zh) | 一种治疗不孕症的药物组合物及其制备方法和用途 | |
CN107875308A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN107898943A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN109568392A (zh) | 一种治疗不孕症的药物组合物及其制备方法和用途 | |
CN107998252A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
CN107929399A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN107875193A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN107812123A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN105535658A (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
CN107823481A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
CN102018787B (zh) | 一种用于降血压的胶囊及制作工艺 | |
CN1048885C (zh) | 一种治疗风湿性心脏病的中成药及其制备方法 | |
CN108042678A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180320 |